Resmetirom
PubChem compound: 15981237
Active ingredient description
Resmetirom is a liver-directed partial agonist for the thyroid hormone receptor beta (THR-β). Stimulation of THR-β in the liver improves mitochondrial function and lipid metabolism, and increases fatty acid β-oxidation, thereby reducing lipotoxic liver fat, inflammation and liver fibrosis. Resmetirom's liver directed THR-β agonism is particularly relevant in the treatment of MASH and leads to minimal off-target activity on THR-α in tissues such as heart and bone.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| A05BA11 | A Alimentary tract and metabolism → A05 Bile and liver therapy → A05B Liver therapy, lipotropics → A05BA Liver therapy | |
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| REZDIFFRA Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| REZDIFFRA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Medicines
Resmetirom is an active ingredient of these brands:
Austria (AT)Estonia (EE)France (FR)Italy (IT)Lithuania (LT)United States (US)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.